Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lonicera japonica, commonly known as Japanese honeysuckle or Jinyinhua, is a prominent medicinal plant in Traditional Chinese Medicine (TCM) valued for its antipyretic, anti-inflammatory, and detoxifying properties. It contains a diverse array of bioactive compounds, including chlorogenic acid, flavonoids (such as luteoloside and lonicerin), and polysaccharides. Research indicates its potential in treating various conditions, including type 2 diabetes, acute lung injury, heart failure, and certain cancers (e.g., thyroid cancer and acute myeloid leukemia). Its mechanisms involve the modulation of inflammatory pathways (NF-κB, Keap1/Nrf2), oxidative stress (STAT3/PGC-1α), and gut microbiota. It is also widely used as a food-medicine resource and a natural preservative.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lonicera japonica.